儿童急性髓系白血病的基因组结构及治疗结局:儿童肿瘤协作组报告
该研究对446例新诊断儿童急性髓系白血病患者进行全基因组基因分型,评估拷贝数改变(CNA)与治疗结局的关联。平均每例患者检出1.14个体细胞获得性CNA,CNA的存在与3年总生存、无事件生存和诱导1结束后复发风险的下降相关。按危险组分析,仅标危组的总生存和无事件生存下降。
要点
- 446例儿童新诊断急性髓系白血病患者中,平均每例检出1.14个体细胞获得性CNA。
- CNA的存在与3年总生存(HR 1.7)、无事件生存(HR 1.4)和复发风险(HR 1.4)下降相关。
- 按危险组分析,仅标危组的总生存(HR 1.9)和无事件生存(HR 1.7)下降。
核心结论
- CNA的存在与儿童急性髓系白血病患者3年总生存、无事件生存和复发风险的下降相关。
- 按危险组分析,仅标危组显示总生存和无事件生存下降。
- 需要进一步研究以检验CNA存在对急性髓系白血病患者疾病复发的预后意义。
研究设计与样本
- 研究纳入446例新诊断儿童急性髓系白血病患者,来自儿童肿瘤协作组(COG)AAML0531、AAML03P1和CCG2961研究。
- 采用Affymetrix和Illumina Omni 2.5平台进行全基因组基因分型,评估拷贝数改变(CNA)及其与治疗结局的关联。
- Affymetrix和Illumina研究数据采用ASCAT和GISTIC软件联合分析。
主要发现
- 平均每例患者检出1.14个体细胞获得性CNA。
- CNA的存在与3年总生存下降相关(HR 1.7;95%CI 1.2-2.4)。
- CNA的存在与3年无事件生存下降相关(HR 1.4;95%CI 1.0-1.8)。
- CNA的存在与诱导1结束后复发风险下降相关(HR 1.4;95%CI 1.0-2.0)。
- 按危险组分析,仅标危组总生存下降(HR 1.9;95%CI 1.1-3.3)和无事件生存下降(HR 1.7;95%CI 1.1-2.6)。
局限性
- 需要进一步研究以检验CNA存在对急性髓系白血病患者疾病复发的预后意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Childhood acute myeloid leukemia (AML) is frequently characterized by chromosomal instability. Approximately 50% of patients have disease relapse, and novel prognostic markers are needed to improve risk stratification. We performed genome-wide genotyping in 446 pediatric patients with de novo AML enrolled in Children's Oncology Group (COG) studies AAML0531, AAML03P1, and CCG2961. Affymetrix and Illumina Omni 2.5 platforms were used to evaluate copy-number alterations (CNAs) and determine their associations with treatment outcome. Data from Affymetrix and Illumina studies were jointly analyzed with ASCAT and GISTIC software. An average of 1.14 somatically acquired CNAs per patient were observed. Novel reoccurring altered genomic regions were identified, and the presence of CNAs was found to be associated with decreased 3-year overall survival (OS), event-free survival (EFS), and relapse risk from the end of induction 1 (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.2-2.4; HR, 1.4; 95% CI, 1.0-1.8; and HR, 1.4; 95% CI, 1.0-2.0, respectively). Analyses by risk group demonstrated decreased OS and EFS in the standard-risk group only (HR, 1.9; 95% CI, 1.1-3.3 and HR, 1.7; 95% CI, 1.1-2.6, respectively). Additional studies are required to test the prognostic significance of CNA presence in disease relapse in patients with AML. COG studies AAML0531, AAML03P1, and CCG2961 were registered at www.clinicaltrials.gov as #NCT01407757, #NCT00070174, and #NCT00003790, respectively.
引用
- Vujkovic M, Attiyeh EF, Ries RE, et al. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. 2017. PMID: 28411282. doi:10.1182/blood-2017-03-772384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。